Tectonic Therapeutic, Inc. (TECX)
US — Healthcare Sector
Peers:
Automate Your Wheel Strategy on TECX
With Tiblio's Option Bot, you can configure your own wheel strategy including TECX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol TECX
- Rev/Share 0.0
- Book/Share 17.5453
- PB 1.1844
- Debt/Equity 0.0087
- CurrentRatio 22.9195
- ROIC -0.2086
- MktCap 388014550.0
- FreeCF/Share -3.6759
- PFCF -6.1522
- PE -6.0773
- Debt/Assets 0.0084
- DivYield 0
- ROE -0.3094
- Rating B-
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 4
- P/B Score 4
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | TECX | Raymond James | -- | Outperform | -- | $76 | June 11, 2025 |
| Initiation | TECX | Mizuho | -- | Outperform | -- | $51 | April 21, 2025 |
| Initiation | TECX | Wells Fargo | -- | Overweight | -- | $55 | Aug. 22, 2024 |
News
Wall Street Analysts See a 258.52% Upside in Tectonic Therapeutic, Inc. (TECX): Can the Stock Really Move This High?
TECX
Published: May 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Published: May 13, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 258.5% upside potential for Tectonic Therapeutic, Inc. (TECX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
About Tectonic Therapeutic, Inc. (TECX)
- IPO Date
- Website https://tectonictx.com
- Industry Biotechnology
- CEO Alise S. Reicin
- Employees 51
Tectonic Therapeutic, Inc., a clinical stage biotechnology company focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G-protein coupled receptors(GPCRs). It offers GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's pipeline products include RXFP1 agonist, which is in ongoing phase 1a and 1b for the indication of heart failure with preserved ejection fraction; GPCR antagonist for indication of hereditary hemorrhagic telangiectasia; bi-functional GPCR modulator for indication of fibrosis; and GPCR modulators. Tectonic Therapeutic, Inc. is based in Watertown, Massachusetts.